Verificando…
Traduzido automaticamente. Doses e advertências: confira o original em inglês. Ler em inglês

Brolucizumab

BEOVU ® is indicated for the treatment of: BEOVU is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of: Neovas.

Checked against the official label · Updated

MEDICAMENTO SUJEITO A RECEITA MÉDICA Intravitreal

Brolucizumab: quick answers

Used for
BEOVU ® is indicated for the treatment of: BEOVU is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Diabetic Macular Edema (DME) ( 1.2 ) 1.1 Neovascular (Wet) Age-related Macular Degeneration…
Children
Prescription
Prescription medicine in the United States; rules differ by country.

From the official label (Oct 2026). Your prescription and pharmacist come first.

How to use Brolucizumab

O que diz a bula oficial. Se um médico receitou, siga a receita. Se a bula da sua caixa for diferente, vale a da sua caixa.

Para quem é

BEOVU ® is indicated for the treatment of: BEOVU is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Diabetic Macular Edema (DME) ( 1.2 ) 1.1 Neovascular (Wet) Age-related Macular Degeneration (AMD) 1.2 Diabetic Macular Edema (DME)

Como tomar e com que frequência
  • Neovascular (Wet) Age-Related Macular Degeneration (AMD) The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) monthly (approximately every 25-31 days) for the first three doses, followed by one dose of 6 mg (0.05 mL) every 8-12 weeks
  • Diabetic Macular Edema (DME) The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) every six weeks (approximately every 39-45 days) for the first five doses, followed by one dose of 6 mg (0.05 mL of 120 mg/mL solution) every 8-12 weeks
  • General Dosing Information For ophthalmic intravitreal injection
  • BEOVU must be administered by a qualified physician
  • BEOVU is available packaged as follows [see How Supplied/Storage and Handling ] : Pre-filled Syringe Vial kit with injection components (vial, filter needle) Neovascular (Wet) Age-Related Macular Degeneration (AMD) The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection monthly (approximately every 25 to 31 days) for the first three doses, followed by 6 mg (0.05 mL) by intravitreal injection once every 8 to 12 weeks
  • Diabetic Macular Edema (DME) The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) administered by intravitreal injection every six weeks (approximately every 39-45 days) for the first five doses, followed by 6 mg (0.05 mL) by intravitreal injection once every 8-12 weeks
  • Preparation for Administration – Pre-filled Syringe and Vial Store BEOVU in the refrigerator between 2°C to 8°C (36°F to 46°F); do not freeze. …
Strengths it comes in

BEOVU is a clear to slightly opalescent and colorless to slightly brownish-yellow solution available as: Intravitreal injection: 6 mg/0.05 mL in a single-dose pre-filled syringe. Intravitreal injection: 6 mg/0.05 mL in a single-dose vial. Intravitreal injection: 6 mg/0.05 mL solution in a single-dose pre-filled syringe ( 3 ). …

Children
  • The safety and efficacy of BEOVU
  • In pediatric patients has not been established
Older adults

In the two Phase 3 clinical studies in AMD, approximately 90% (978/1089) of patients randomized to treatment with BEOVU were ≥ 65 years of age and approximately 60% (648/1089) were ≥ 75 years of age. In the two Phase 3 clinical studies in DME, approximately 45% (164/368) of patients randomized to treatment with BEOVU were ≥ 65 years of age and approximately 10% (37/368) were ≥ 75 years of age. …

While you are taking it
  • Advise patients that in the days following BEOVU administration, patients are at risk of developing endophthalmitis, retinal detachment, retinal vasculitis and/or retinal vascular occlusion
  • If the eye becomes red, sensitive to light, painful, or if a patient develops any change in vision, instruct the patient to seek immediate care from an ophthalmologist [see Warnings and Precautions ]
  • Patients may experience temporary visual disturbances after an intravitreal injection with BEOVU and the associated eye examination [see Adverse Reactions ]
  • Advise patients not to drive or use machinery until visual function has recovered sufficiently. …
Talk to a doctor first if
  • Ocular or Periocular Infections Active Intraocular Inflammation Hypersensitivity Ocular or Periocular Infections BEOVU is contraindicated in patients with ocular or periocular infections
  • Active Intraocular Inflammation BEOVU is contraindicated in patients with active intraocular inflammation
  • Hypersensitivity BEOVU is contraindicated in patients with known hypersensitivity to brolucizumab or any of the excipients in BEOVU. …
Warnings

Endophthalmitis and retinal detachment may occur following intravitreal injections. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay ( 5.1 ). Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported following BEOVU injections. Patients should be instructed to report any change in vision without delay ( 5.2 ). Increases in intraocular pressure (IOP) have been seen within 30 minutes of an intravitreal injection ( 5.3 ). There is a potential risk of arterial thromboembolic events (ATE) following intravitreal use of VEGF inhibitors ( 5.4 ). …

Possíveis efeitos colaterais

The following potentially serious adverse reactions are described elsewhere in the labeling: Hypersensitivity [see Contraindications (4.3)] Endophthalmitis and Retinal Detachment [see Warnings and Precautions (5.1)] Retinal Vasculitis and/or Retinal Vascular Occlusion [see Warnings and Precautions (5.2)] Increase in Intraocular Pressure [see Warnings and Precautions (5.3)] Thromboembolic Events [see Warnings and Precautions (5.4)] The most common adverse reactions reported in patients receiving BEOVU are vision blurred, cataract, conjunctival hemorrhage, eye pain, and vitreous floaters ( 6.1 ). …

Pregnancy and breastfeeding

8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies of BEOVU administration in pregnant women. In an animal reproduction study, intravitreal administration of brolucizumab to pregnant monkeys once every 4 weeks in one eye from organogenesis to birth did not indicate any harmful effects with respect to pre- or postnatal development at 10-fold the maximum recommended human dose (MRHD) on a mg/kg basis ( see Data ). …

Se esquecer uma dose

Tome assim que lembrar, a menos que esteja quase na hora da próxima dose. Nesse caso, pule a dose esquecida. Nunca tome duas doses de uma vez para compensar. Confira a bula, pois alguns medicamentos são diferentes.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2026-10-26.

How much Brolucizumab costs

In other countries

Prices in other countries are not what you will pay where you live; they show how prices compare.

Marcas pelo mundo

Products with Brolucizumab as the active ingredient. Names differ between countries.

Registered products

United States (FDA)

BrolucizumabBROLUCIZUMAB 127 mg/mL · Solution · Lonza AG
NDC 49187-0226Label
BeovuBROLUCIZUMAB 6 mg/.05mL · Injection, Solution · Novartis Pharmaceuticals Corporation
NDC 0078-0827Label

Nigeria (NAFDAC)

NAFDACPagenax 120 mg/mL Solution for Injection A6-100100

Other countries: check your pack's registration number and we point you to your regulator.

Check your pack of Brolucizumab

Type the registration number on the pack, or scan it with your camera.

Ou tire fotos da caixa
Restam 3 verificações grátis hoje Official sources: U.S. FDA · EMA (EU) · Health Canada · WHO alerts

Questions about Brolucizumab

What is Brolucizumab used for?

BEOVU ® is indicated for the treatment of: BEOVU is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Diabetic Macular Edema (DME) ( 1.2 ) 1.1 Neovascular (Wet) Age-related Macular Degeneration (AMD) 1.2 Diabetic Macular Edema (DME) (From the official U.S. FDA label.)

How do I take Brolucizumab?

Follow your prescription or the leaflet in your pack. The official label says: Neovascular (Wet) Age-Related Macular Degeneration (AMD) The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) monthly (approximately every 25-31 days) for the first three doses, followed by one dose of 6 mg (0.05 mL) every 8-12 weeks ( 2.2 ). Diabetic Macular Edema (DME) The recommended dose for BEOVU is 6 mg (0.05 mL of 120 mg/mL solution) every six weeks (ap…

Can I drive after taking Brolucizumab?

Advise patients not to drive or use machinery until visual function has recovered sufficiently.

Do I need a prescription for Brolucizumab?

Usually yes. Brolucizumab is a prescription medicine in most countries. Rules differ by country.

What brands contain Brolucizumab?

Brolucizumab is sold under names such as Beovu. Brand names differ between countries.

What are the side effects of Brolucizumab?

The official label lists: The following potentially serious adverse reactions are described elsewhere in the labeling: Hypersensitivity [see Contraindications (4.3)] Endophthalmitis and Retinal Detachment [see Warnings and Precautions (5.1)] Retinal Vasculitis and/or Retinal Vascular Occlusion [see Warnings and Precautions (5.2)] Increase in Intraocular Pressure [see Warnings and Precautions (5.3)] Thro… Tell your doctor about any side effect that bothers you or does not go away.

Can children take Brolucizumab?

The safety and efficacy of BEOVU in pediatric patients has not been established. Always use the dose for the child's age or weight on the pack or prescription.

Can I take Brolucizumab when pregnant or breastfeeding?

8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies of BEOVU administration in pregnant women. In an animal reproduction study, intravitreal administration of brolucizumab to pregnant monkeys once every 4 weeks in one eye from organogenesis to birth did not indicate any harmful effects with respect to pre- or postnatal development at 10-fold the maximum… Ask your doctor or midwife first.

How can I check that my Brolucizumab is genuine?

Scan the registration number on your pack with PillVera (NAFDAC number in Nigeria, NDC in the United States, DIN in Canada), check the expiry date and buy only from licensed pharmacies.

Sources

This page shows what official sources say, in plain words. It is not medical advice: your prescription and your doctor or pharmacist come first. Brand names, strengths and rules differ between countries.